Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG. Bass JK, et al. Among authors: cohn rj. Pediatr Blood Cancer. 2014 Apr;61(4):601-5. doi: 10.1002/pbc.24830. Epub 2013 Nov 1. Pediatr Blood Cancer. 2014. PMID: 24504791 Free PMC article.
Treatment of children with poor risk solid tumors by further escalation of the VETOPEC regimen including very high-dose cyclophosphamide and peripheral stem cell support: an Australian and New Zealand Children's Hematology and Oncology Group study.
McCowage GB, Mrongovius R, Alvaro F, Cohn RJ, Ziegler DS, Oswald C, White L; Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG). McCowage GB, et al. Among authors: cohn rj. Pediatr Blood Cancer. 2011 Dec 1;57(6):958-64. doi: 10.1002/pbc.23042. Epub 2011 Jul 25. Pediatr Blood Cancer. 2011. PMID: 21793175 Clinical Trial.
Novel mutations target distinct subgroups of medulloblastoma.
Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R, Kriwacki R, Curley N, Thiruvenkatam R, Wang J, Wu G, Rusch M, Hong X, Becksfort J, Gupta P, Ma J, Easton J, Vadodaria B, Onar-Thomas A, Lin T, Li S, Pounds S, Paugh S, Zhao D, Kawauchi D, Roussel MF, Finkelstein D, Ellison DW, Lau CC, Bouffet E, Hassall T, Gururangan S, Cohn R, Fulton RS, Fulton LL, Dooling DJ, Ochoa K, Gajjar A, Mardis ER, Wilson RK, Downing JR, Zhang J, Gilbertson RJ. Robinson G, et al. Among authors: cohn r. Nature. 2012 Aug 2;488(7409):43-8. doi: 10.1038/nature11213. Nature. 2012. PMID: 22722829 Free PMC article.
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.
Gottardo NG, Hansford JR, McGlade JP, Alvaro F, Ashley DM, Bailey S, Baker DL, Bourdeaut F, Cho YJ, Clay M, Clifford SC, Cohn RJ, Cole CH, Dallas PB, Downie P, Doz F, Ellison DW, Endersby R, Fisher PG, Hassall T, Heath JA, Hii HL, Jones DT, Junckerstorff R, Kellie S, Kool M, Kotecha RS, Lichter P, Laughton SJ, Lee S, McCowage G, Northcott PA, Olson JM, Packer RJ, Pfister SM, Pietsch T, Pizer B, Pomeroy SL, Remke M, Robinson GW, Rutkowski S, Schoep T, Shelat AA, Stewart CF, Sullivan M, Taylor MD, Wainwright B, Walwyn T, Weiss WA, Williamson D, Gajjar A. Gottardo NG, et al. Among authors: cohn rj. Acta Neuropathol. 2014 Feb;127(2):189-201. doi: 10.1007/s00401-013-1213-7. Epub 2013 Nov 22. Acta Neuropathol. 2014. PMID: 24264598 Free PMC article.
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath JA, Kellie S, Cohn R, Fisher MJ, Panandiker AP, Merchant TE, Srinivasan A, Wetmore C, Qaddoumi I, Stewart CF, Armstrong GT, Broniscer A, Gajjar A. Gurney JG, et al. Neuro Oncol. 2014 Jun;16(6):848-55. doi: 10.1093/neuonc/not241. Epub 2014 Jan 10. Neuro Oncol. 2014. PMID: 24414535 Free PMC article. Clinical Trial.
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ. Xu H, et al. Nat Genet. 2015 Mar;47(3):263-6. doi: 10.1038/ng.3217. Epub 2015 Feb 9. Nat Genet. 2015. PMID: 25665007 Free PMC article.
231 results